Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Aprotinin Plasminogen Antifibrinolytic Action Pathway
Homo sapiens
Drug Action Pathway
Aprotinin is an inhibitor that is used to prevent blood loss during cardiopulmonary bypass surgery. It slows the breakdown of fibrin clots to reduce bleeding by inhibiting the proteins plasminogen and kallikrein. The drug is slowly metabolized by lysosomal enzymes and is eliminated through the urine over 48 hours. The drug was withdrawn worldwide due to the enhanced risks associated with its use leading to various complications and in some cases death.
References
Aprotinin Plasminogen Antifibrinolytic Pathway References
Davis R, Whittington R: Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs. 1995 Jun;49(6):954-83. doi: 10.2165/00003495-199549060-00008.
Pubmed: 7543841
Levy JH, Sypniewski E: Aprotinin: a pharmacologic overview. Orthopedics. 2004 Jun;27(6 Suppl):s653-8. doi: 10.3928/0147-7447-20040602-05.
Pubmed: 15239552
De Hert S, Ouattara A, Royston D, van der Linden J, Zacharowski K: Use and safety of aprotinin in routine clinical practice: A European postauthorisation safety study conducted in patients undergoing cardiac surgery. Eur J Anaesthesiol. 2022 Aug 1;39(8):685-694. doi: 10.1097/EJA.0000000000001710. Epub 2022 Jun 29.
Pubmed: 35766393
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings